Johnson & Johnson's DePuy unit has faced plenty of pushback the past few years over its all-metal hip implants, with patients suing the company for alleged design defects causing pain and injury. Now the company is in the hot seat again, and this time, it's for manufacturing problems in the U.K. linked to the devices.
Scientists have developed brain implants to monitor pressure and temperature after traumatic brain injury that dissolve over a few days. The idea is that these could be implanted during surgery on TBI patients in order to conduct subsequent monitoring, but then they would not require removal.
After a reverse merger in December, the blood glucose monitor implant company Senseonics is already publicly traded, albeit on the OTC markets. Now, it's filed to raise up to $51.8 million in an IPO-like offering, after which it proposes to bump up to the NYSE market and trade under the ticker symbol "SENS."
Smith & Nephew sees the arthroscopically delivered cartilage repair solution it's just bought from Montreal, Canada-based Piramal for an undisclosed sum as a first-line treatment. Known as BST-CarGel, it's approved in most of Europe, Australia and Canada.
Johnson & Johnson Innovation and JJDC, the innovation-focused arms of Johnson & Johnson, have co-led a $15 million financing for CartiHeal to back its cell-free, tissue-regenerating implant called Agili-C that has a CE mark. The implant is used for procedures in the knee, ankle and big toe that indicate a need for regeneration of cartilage and the underlying bone, in addition to reduction in pain and other related symptoms.
The U.S. National Institutes of Health is financing what's expected to be the largest long-term clinical study for an artificial pancreas to regulate the blood sugar levels in Type 1 diabetics to the tune of $12.7 million. This is the biggest chunk it's yet doled out as part of a program the agency started in 2014 to promote testing of artificial pancreas systems that's already backed at least three other research efforts.
CryoLife is slated to buy Austin, TX-based startup On-X Life Technologies for $130 million in cash and stock. The Atlanta, GA-based acquirer specializes in tissue implants and medical devices for cardiac and vascular surgical use; the deal will add the On-X aortic valve as well as other marketed valve products.
Axonics Modulation Technologies has gained $38.5 million in a Series B round to start a study of its overactive bladder implant in Europe and North America early next year.
The notion of human tissue-integrated biosensors to monitor chronic disease and health indicators may seem a bit outlandish. But startup Profusa has gotten some serious buy-in from investors and advisers to back precisely that vision--to provide real-time, minimally invasive monitoring of body chemistries.
The U.S. Food and Drug Administration has issued a safety communication regarding a wide array of intravascular implanted devices and delivery tools that have coatings designed to reduce friction and improve maneuverability.